Literature DB >> 8786814

GM2 ganglioside and pyramidal neuron dendritogenesis.

S U Walkley1, D A Siegel, K Dobrenis.   

Abstract

GM2 ganglioside, although scarce in normal adult brain, is the predominant ganglioside accumulating in several types of lysosomal disorders, most notably Tay-Sachs disease. Pyramidal neurons of cerebral cortex in Tay-Sachs, as well as many other types of neuronal storage disorders, are known to exhibit a phenomenon believed unique to storage disorders: growth of ectopic dendrites. Recent studies have shown that a common metabolic abnormality shared by storage diseases with ectopic dendrite growth is the abnormal accumulation of GM2 ganglioside. The correlation between increased levels of GM2 and the presence of ectopic dendrites has been found in both ganglioside and nonganglioside storage disorders, the latter including sphingomyelin-cholesterol lipidosis, mucopolysaccharidosis, and alpha-mannosidosis. Quantitative HPTLC analysis has shown that increases in GM2 occur in proportion to the incidence of ectopic dendrite growth, whereas other gangliosides, including GM1, lack similar increases. Immunocytochemical studies of all nonganglioside storage diseases which exhibit ectopic dendritogenesis have revealed heightened GM2 ganglioside-immunoreactivity in the cortical pyramidal cell population, whereas nerurons in normal adult brain exhibit little or no staining for this ganglioside. Further, studies examining disease development have consistently shown that accumulation of GM2 ganglioside precedes growth of ectopic dendrites, indicating that it is not simply occurring secondary to new membrane production. These findings have prompted an examination for a similar relationship between GM2 ganglioside and dendritogenesis in cortical neurons of normal developing brain. Results show that GM2 ganglioside-immunoreactivity is consistently elevated in immature neurons during the period when they are undergoing active dendritic initiation, but this staining diminishes dramatically as the dendritic trees of these cells mature. Collectively, these studies on diseased and normal brain offer compelling evidence that GM2 ganglioside plays a pivotal role in the regulation of dendritogenesis in cortical pyramidal neurons.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8786814     DOI: 10.1007/bf00992503

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  98 in total

1.  Altered phosphoinositide-specific phospholipase C and adenylyl cyclase in brain cortical membranes of cats with GM1 and GM2 gangliosidosis.

Authors:  E Claro; M A Wallace; J N Fain; B G Nair; T B Patel; G Shanker; H J Baker
Journal:  Brain Res Mol Brain Res       Date:  1991-10

2.  Distribution of ectopic neurite growth and other geometrical distortions of CNS neurons in feline GM2 gangliosidosis.

Authors:  S U Walkley; S Wurzelmann; M C Rattazzi; H J Baker
Journal:  Brain Res       Date:  1990-02-26       Impact factor: 3.252

3.  Use of brefeldin A to define sites of glycosphingolipid synthesis: GA2/GM2/GD2 synthase is trans to the brefeldin A block.

Authors:  W W Young; M S Lutz; S E Mills; S Lechler-Osborn
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

4.  The synthesis of complex carbohydrates by multiglycosyltransferase systems and their potential function in intercellular adhesion.

Authors:  S Roseman
Journal:  Chem Phys Lipids       Date:  1970-10       Impact factor: 3.329

5.  Oligosialogangliosides inhibit GM2- and GD3-synthesis in isolated Golgi vesicles from rat liver.

Authors:  H K Yusuf; G Schwarzmann; G Pohlentz; K Sandhoff
Journal:  Biol Chem Hoppe Seyler       Date:  1987-05

6.  Ganglioside-induced neuritogenesis: verification that gangliosides are the active agents, and comparison of molecular species.

Authors:  M C Byrne; R W Ledeen; F J Roisen; G Yorke; J R Sclafani
Journal:  J Neurochem       Date:  1983-11       Impact factor: 5.372

7.  Ectopic dendrites occur only on cortical pyramidal cells containing elevated GM2 ganglioside in alpha-mannosidosis.

Authors:  L A Goodman; P O Livingston; S U Walkley
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

8.  Developmental changes in ganglioside composition and synthesis in embryonic rat brain.

Authors:  R K Yu; L J Macala; T Taki; H M Weinfield; F S Yu
Journal:  J Neurochem       Date:  1988-06       Impact factor: 5.372

9.  Modified ganglioside as a possible modulator of transmembrane signaling mechanism through growth factor receptors: a preliminary note.

Authors:  N Hanai; G Nores; C R Torres-Méndez; S Hakomori
Journal:  Biochem Biophys Res Commun       Date:  1987-08-31       Impact factor: 3.575

10.  Gangliosides, the thyrotropin receptor, and autoimmune thyroid disease.

Authors:  P Lacetti; D Tombaccini; S Aloj; E F Grollman; L D Kohn
Journal:  Adv Exp Med Biol       Date:  1984       Impact factor: 2.622

View more
  9 in total

1.  Cerebellar alterations and gait defects as therapeutic outcome measures for enzyme replacement therapy in α-mannosidosis.

Authors:  Markus Damme; Stijn Stroobants; Steven U Walkley; Renate Lüllmann-Rauch; Rudi D'Hooge; Jens Fogh; Paul Saftig; Torben Lübke; Judith Blanz
Journal:  J Neuropathol Exp Neurol       Date:  2011-01       Impact factor: 3.685

Review 2.  Sphingolipids and cell signalling.

Authors:  P Fredman
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

3.  Chronic subdural hematoma associated with mucopolysaccharidosis type III B (Sanfilippo's syndrome B).

Authors:  Toshinari Kawasaki; Masashi Kitagawa; Keita Suzuki; Takafumi Wataya
Journal:  Childs Nerv Syst       Date:  2016-03-07       Impact factor: 1.475

4.  Anti-GM2 ganglioside antibodies are a biomarker for acute canine polyradiculoneuritis.

Authors:  Angie Rupp; Francesc Galban-Horcajo; Ezio Bianchi; Maurizio Dondi; Jacques Penderis; Joanna Cappell; Karl Burgess; Kaspar Matiasek; Rhona McGonigal; Hugh J Willison
Journal:  J Peripher Nerv Syst       Date:  2013-03       Impact factor: 3.494

Review 5.  Sanfilippo syndrome: a mini-review.

Authors:  M J Valstar; G J G Ruijter; O P van Diggelen; B J Poorthuis; F A Wijburg
Journal:  J Inherit Metab Dis       Date:  2008-04-04       Impact factor: 4.982

6.  Characterization of inducible models of Tay-Sachs and related disease.

Authors:  Timothy J Sargeant; Deborah J Drage; Susan Wang; Apostolos A Apostolakis; Timothy M Cox; M Begoña Cachón-González
Journal:  PLoS Genet       Date:  2012-09-20       Impact factor: 5.917

7.  Electrophysiological and Histological Characterization of Rod-Cone Retinal Degeneration and Microglia Activation in a Mouse Model of Mucopolysaccharidosis Type IIIB.

Authors:  Dennis Y Tse; Parisa Lotfi; David L Simons; Marco Sardiello; Samuel M Wu
Journal:  Sci Rep       Date:  2015-11-26       Impact factor: 4.379

8.  A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II.

Authors:  Hiroyuki Sonoda; Hideto Morimoto; Eiji Yoden; Yuri Koshimura; Masafumi Kinoshita; Galina Golovina; Haruna Takagi; Ryuji Yamamoto; Kohtaro Minami; Akira Mizoguchi; Katsuhiko Tachibana; Tohru Hirato; Kenichi Takahashi
Journal:  Mol Ther       Date:  2018-03-06       Impact factor: 11.454

9.  Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial.

Authors:  Torayuki Okuyama; Yoshikatsu Eto; Norio Sakai; Kohtaro Minami; Tatsuyoshi Yamamoto; Hiroyuki Sonoda; Mariko Yamaoka; Katsuhiko Tachibana; Tohru Hirato; Yuji Sato
Journal:  Mol Ther       Date:  2018-12-08       Impact factor: 11.454

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.